Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Licenses Data from Genaissance s STRENGTH Statin Study

NEW YORK, Sept. 11 (GenomeWeb News) - AstraZeneca has licensed data from Genaissance Pharmaceutical's so-called STRENGTH study, the company said today.

Terms of the agreement call for AstraZeneca to receive non-exclusive access to the database, which it will use for "a limited period."

This STRENGTH study -- or Statin Response Examined by Genetic Haplotype Markers -- followed more than 400 patients and showed that gene mutations influence a patient's response to the statin class of antihypercholesterolemia drugs.

The 16-week study prospectively analyzed for an association between an individual's haplotypes and the effectiveness of three statins -- atorvastatin, pravastatin, and simvastatin -- in reducing LDL- cholesterol.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.